Kathleen BA - Abcellera BiologicsInc Head Communications
| ABCL Stock | USD 3.64 0.14 3.70% |
Executive
Kathleen BA is Head Communications of Abcellera BiologicsInc
| Address | 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1 |
| Phone | 604-559-9005 |
| Web | https://www.abcellera.com |
Abcellera BiologicsInc Management Efficiency
The company has return on total asset (ROA) of (0.0979) % which means that it has lost $0.0979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1227) %, meaning that it created substantial loss on money invested by shareholders. Abcellera BiologicsInc's management efficiency ratios could be used to measure how well Abcellera BiologicsInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.11 this year. Return On Capital Employed is expected to rise to -0.16 this year. At this time, Abcellera BiologicsInc's Net Tangible Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 23.1 M this year, although the value of Non Current Assets Total will most likely fall to about 317.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ulrike MD | CureVac NV | 51 | |
| Francesca Nolan | Sarepta Therapeutics | N/A | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| David Chien | Krystal Biotech | N/A | |
| Hubert MD | Krystal Biotech | 55 | |
| Christine Utter | PTC Therapeutics | 46 | |
| Patrick Baumhof | CureVac NV | N/A | |
| Ram Kamineni | Krystal Biotech | N/A | |
| Dallan Murray | Sarepta Therapeutics | N/A | |
| Jennifer McDonough | Krystal Biotech | N/A | |
| Jane Baj | PTC Therapeutics | N/A | |
| Hege SollieZetlmayer | PTC Therapeutics | N/A | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| Bilal Arif | Sarepta Therapeutics | 52 | |
| James MBA | Iovance Biotherapeutics | N/A | |
| Laurent Goux | Krystal Biotech | N/A | |
| Steven JD | AVROBIO | 62 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| Meg Dodge | Krystal Biotech | N/A | |
| Heather Armstrong | Vir Biotechnology | N/A | |
Management Performance
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0979 |
Abcellera BiologicsInc Leadership Team
Elected by the shareholders, the Abcellera BiologicsInc's board of directors comprises two types of representatives: Abcellera BiologicsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abcellera. The board's role is to monitor Abcellera BiologicsInc's management team and ensure that shareholders' interests are well served. Abcellera BiologicsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abcellera BiologicsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Veronique Lecault, COO Director | ||
| Bo Barnhart, Scientific Director | ||
| Andrew MBA, Chief Officer | ||
| JD Esq, Chief Officer | ||
| Murray McCutcheon, Senior Partnering | ||
| M CIPD, Sr Culture | ||
| Ester Falconer, Chief Officer | ||
| Alexandra MSc, Ma Communications | ||
| Esq JD, CCO, Officer | ||
| Josephine Hellschlienger, Manager Relations | ||
| Tiffany BSc, VP Communications | ||
| Neil MBA, Chief Officer | ||
| Carl Hansen, President CEO | ||
| CGA CPA, Senior Accounting | ||
| Graham MSc, Director Development | ||
| Kathleen BA, Head Communications |
Abcellera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abcellera BiologicsInc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0979 | ||||
| Operating Margin | (7.20) % | ||||
| Current Valuation | 499.63 M | ||||
| Shares Outstanding | 294.05 M | ||||
| Shares Owned By Insiders | 27.90 % | ||||
| Shares Owned By Institutions | 42.91 % | ||||
| Number Of Shares Shorted | 23.29 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 1.10 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Abcellera BiologicsInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.Note that the Abcellera BiologicsInc information on this page should be used as a complementary analysis to other Abcellera BiologicsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Abcellera Stock analysis
When running Abcellera BiologicsInc's price analysis, check to measure Abcellera BiologicsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera BiologicsInc is operating at the current time. Most of Abcellera BiologicsInc's value examination focuses on studying past and present price action to predict the probability of Abcellera BiologicsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abcellera BiologicsInc's price. Additionally, you may evaluate how the addition of Abcellera BiologicsInc to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Abcellera BiologicsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera BiologicsInc. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera BiologicsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.51) | Revenue Per Share 0.131 | Quarterly Revenue Growth (0.57) | Return On Assets (0.1) |
The market value of Abcellera BiologicsInc is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera BiologicsInc's value that differs from its market value or its book value, called intrinsic value, which is Abcellera BiologicsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera BiologicsInc's market value can be influenced by many factors that don't directly affect Abcellera BiologicsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera BiologicsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera BiologicsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera BiologicsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.